Tags

Type your tag names separated by a space and hit enter

COVID-19 vaccines.
Curr Opin Immunol. 2021 08; 71:111-116.CO

Abstract

COVID-19 is a pandemic of unprecedented proportions in recent human history. Less than 18 months since the onset of the pandemic, there are close to two hundred million confirmed cases and four million deaths worldwide. There have also been massive efforts geared towards finding safe and effective vaccines. By July 2021 there were 184 COVID-19 vaccine candidates in pre-clinical development, 105 in clinical development, and 18 vaccines approved for emergency use by at least one regulatory authority. These vaccines include whole virus live attenuated or inactivated, protein-based, viral vector, and nucleic acid vaccines. By mid-2021 three billion doses of COVID-19 vaccine have been administered around the world, mostly in high-income countries. COVID-19 vaccination provides hope for an end to the pandemic, if and only if there would be equal access and optimal uptake in all countries around the world.

Links

PMC Free PDF

Authors+Show Affiliations

Ndwandwe D
Cochrane South Africa, South African Medical Research Council, Parow Valley, 7501, Cape Town, South Africa. Electronic address: Duduzile.ndwandwe@mrc.ac.za.
Wiysonge CS
Cochrane South Africa, South African Medical Research Council, Parow Valley, 7501, Cape Town, South Africa; Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, 7505, Cape Town, South Africa; School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, 7925, Cape Town, South Africa.

MeSH

COVID-19COVID-19 VaccinesHumansPandemicsSARS-CoV-2Vaccines, DNAVaccines, Inactivated

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

34330017

Citation

Ndwandwe, Duduzile, and Charles S. Wiysonge. "COVID-19 Vaccines." Current Opinion in Immunology, vol. 71, 2021, pp. 111-116.
Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021;71:111-116.
Ndwandwe, D., & Wiysonge, C. S. (2021). COVID-19 vaccines. Current Opinion in Immunology, 71, 111-116. https://doi.org/10.1016/j.coi.2021.07.003
Ndwandwe D, Wiysonge CS. COVID-19 Vaccines. Curr Opin Immunol. 2021;71:111-116. PubMed PMID: 34330017.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19 vaccines. AU - Ndwandwe,Duduzile, AU - Wiysonge,Charles S, Y1 - 2021/07/12/ PY - 2021/07/02/received PY - 2021/07/05/accepted PY - 2021/7/31/pubmed PY - 2021/9/22/medline PY - 2021/7/30/entrez SP - 111 EP - 116 JF - Current opinion in immunology JO - Curr Opin Immunol VL - 71 N2 - COVID-19 is a pandemic of unprecedented proportions in recent human history. Less than 18 months since the onset of the pandemic, there are close to two hundred million confirmed cases and four million deaths worldwide. There have also been massive efforts geared towards finding safe and effective vaccines. By July 2021 there were 184 COVID-19 vaccine candidates in pre-clinical development, 105 in clinical development, and 18 vaccines approved for emergency use by at least one regulatory authority. These vaccines include whole virus live attenuated or inactivated, protein-based, viral vector, and nucleic acid vaccines. By mid-2021 three billion doses of COVID-19 vaccine have been administered around the world, mostly in high-income countries. COVID-19 vaccination provides hope for an end to the pandemic, if and only if there would be equal access and optimal uptake in all countries around the world. SN - 1879-0372 UR - https://www.unboundmedicine.com/medline/citation/34330017/COVID_19_vaccines_ DB - PRIME DP - Unbound Medicine ER -